131391-65-6
Chemical Structure
N-Methyl Leukotriene C4
Synonym(s): N-Methyl-LTC4
- CAS No.: 131391-65-6
- Formula:C31H49N3O9S
- Molecular Weight:639.80
IUPAC Name: (5S,6R,7E,9E,11Z,14Z)-6-(((R)-2-((S)-4-carboxy-4-(methylamino)butanamido)-3-((carboxymethyl)amino)-3-oxopropyl)thio)-5-hydroxyicosa-7,9,11,14-tetraenoic acid
InChIKey: FPLBRCJNODNRQZ-UYCXAPQFSA-N
SMILES: OC(CCC[C@H](O)[C@@H](/C=C/C=C/C=C\C/C=C\CCCCC)SC[C@@H](C(NCC(O)=O)=O)NC(CC[C@H](NC)C(O)=O)=O)=O
Biological Activity: N-Methyl Leukotriene C4 (N-Methyl-LTC4) is a non-metabolizable LTC4 analog and a selective cysteinyl leukotriene receptor 2 (CysLT2) agonist, with an EC50 of 46.1 nM for mouse CysLT2 and an EC50 value of 122.3 nM for human CysLT2. N-Methyl Leukotriene C4 shows low potency against CysLT1. N-Methyl Leukotriene C4 activates human and mouse CysLT2 receptors, triggering calcium signaling, β-arrestin-2 binding to phosphorylated receptors, vascular leakage, hypotension, tachycardia, contraction of guinea pig ileum and trachea, mild bronchoconstriction, as well as hypertension associated with peripheral vasoconstriction. N-Methyl Leukotriene C4 can be used in research on asthma, rhinitis, sinusitis, cerebral inflammation and edema, pulmonary arterial hypertension, and cardiovascular diseases[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N-Methyl Leukotriene C4 | 98.1% | N-Methyl Leukotriene C4 (N-Methyl-LTC4) is a non-metabolizable LTC4 analog and a selective cysteinyl leukotriene receptor 2 (CysLT2) agonist, with an EC50 of 46.1 nM for mouse CysLT2 and an EC50 value of 122.3 nM for human CysLT2. N-Methyl Leukotriene C4 shows low potency against CysLT1. N-Methyl Leukotriene C4 activates human and mouse CysLT2 receptors, triggering calcium signaling, β-arrestin-2 binding to phosphorylated receptors, vascular leakage, hypotension, tachycardia, contraction of guinea pig ileum and trachea, mild bronchoconstriction, as well as hypertension associated with peripheral vasoconstriction. N-Methyl Leukotriene C4 can be used in research on asthma, rhinitis, sinusitis, cerebral inflammation and edema, pulmonary arterial hypertension, and cardiovascular diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yan D, et al. Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays. Mol Pharmacol. 2011 Feb;79(2):270-8. [Content Brief]
- [2]. Sun J, et al. Cardiovascular effects of N-methyl leukotriene C4, a nonmetabolizable leukotriene C4 analogue, and the antagonism of leukotriene-induced hypotension by Ro 23-3544, in the American bullfrog, Rana catesbeiana. Canadian journal of physiology and pharmacology. 1995 Mar;73(3):383-9. [Content Brief]
- [3]. Baker SR, et al. The pharmacology of N-methyl LTC4; a metabolically stable LTC4-mimetic. Prostaglandins. 1990 Nov;40(5):445-61. [Content Brief]
